<DOC>
	<DOCNO>NCT01364688</DOCNO>
	<brief_summary>Active vitamin D therapeutic dose may prevent vascular calcification supraphysiologic dose may precipitate .</brief_summary>
	<brief_title>Oral Alfacalcidol Coronary Artery Calcification Predialysis Chronic Kidney Disease</brief_title>
	<detailed_description>Active vitamin D compound use frequently treatment hyperparathyroidism chronic kidney disease . Recent evidence animal study suggest low dose active vitamin D may protective vascular calcification , whereas high dose could precipitate . The present study examine effect low dose oral alfacalcidol coronary artery calcification predialysis chronic kidney disease patient hyperparathyroidism .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Calcinosis</mesh_term>
	<mesh_term>Vascular Calcification</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<criteria>Predialysis chronic kidney disease GFR &lt; 90 mL/min/1.73m2 PTH upper limit normal serum calcium phosphate upper limit normal change GFR &gt; 15 % past 3 month receive elemental calcium &gt; 500 mg/day currently take active vitamin D , oral calcium elemental calcium &gt; 500 mg/day bisphosphonate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>coronary calcification</keyword>
	<keyword>vascular calcification</keyword>
	<keyword>active vitamin D</keyword>
	<keyword>alfacalcidol</keyword>
</DOC>